Covaxin: Application for clinical trials of innovative drug GB19 injection approved by FDA.

Sina Finance News on March 30th, Kexing Pharmaceuticals announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received a notification from the U.S. Food and Drug Administration (FDA) that its self-developed innovative drug GB19 injection clinical trial application has been approved by the FDA and can be conducted in the United States. It is indicated for the treatment of discoid lupus erythematosus and systemic lupus erythematosus.